MNPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Monopar Therapeutics Inc (MNPR) is not a strong buy at this time for a beginner investor with a long-term focus. The technical indicators are bearish, the financial performance is weak, and there are no significant positive trading trends or proprietary trading signals. While the recent clinical trial results are promising, they are not immediate catalysts for price growth, and the company's financial health raises concerns for long-term investment.
The technical indicators are bearish. The MACD is negatively expanding (-0.271), the RSI is neutral at 31.919, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 52.559), with resistance levels at R1: 58.992 and R2: 60.979.
Monopar released positive clinical trial results for ALXN1840, showing significant neurologic improvements in Wilson disease patients. The company plans to submit a New Drug Application to the FDA in mid-2026, indicating potential long-term growth opportunities.
Additionally, there are no significant insider or hedge fund trading trends, and the stock's technical indicators are bearish.
In Q4 2025, Monopar reported zero revenue growth (0.00% YoY), a net income drop to -$5,200,795 (-52.40% YoY), and a significant EPS decline to -0.61 (-72.65% YoY). Gross margin remained at 0, showing no improvement.
No analyst rating or price target changes are available for MNPR at this time.
